SEC Form 4 · accession 0001104659-16-095539
AGILE THERAPEUTICS INC · AGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katie MacFarlane
Officer — Chief Commercial Officer
Period of report
Feb 8, 2016
Accepted (ET)
Feb 10, 2016 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261249
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $5.93 | Feb 8, 2016 | A | 35,000 | A | — | Feb 7, 2026 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1This option was granted on February 8, 2016. 25% of the shares subject to the stock option vest on February 8, 2017, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on February 8, 2020.